- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01095003
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This multicentre, open-label, randomised, Phase III study will enrol 764 patients with advanced breast cancer who have previously been treated with or are resistant to an anthracycline and who are taxane resistant. Patients will be randomised in a 1:1 ratio to receive vinflunine plus capecitabine (Arm A) or capecitabine alone (Arm B).
Randomisation will be stratified according to a minimization procedure:
- Resistance to anthracyclines ("yes" versus "no"), Relapse ≤ 12 months in the adjuvant or neoadjuvant setting or progression ≤ 4 months in the metastatic setting,
- Karnofsky performance status ("90-100" versus "70-80"),
- Measurable disease ("yes" versus "no"),
- The number of prior lines of chemotherapy in the metastatic setting ("0" versus "1" versus "> 1") and,
- Study site.
Patients randomised in Arm A will receive:
- Vinflunine at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute i.v. infusion and,
- Capecitabine which will be self-administered by the patient in an outpatient setting. Patients will take 825 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.
For patients randomised in Arm B, capecitabine will be self administered by the patient in an outpatient setting. Patients will take 1250 mg/m² twice daily per os for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest. A cycle of therapy is defined as 3 weeks.
The doses and timing of treatment will be modified based on toxicities experienced by the patient.
Patients will be assessed for toxicity, tumour response and progression at regular intervals during treatment. Patients will be evaluated for safety if they received any study drug. Laboratory values, adverse events and other symptoms will be graded.
Tumour response, progression-free survival and duration of response will be evaluated for all randomised patients. Tumour assessment is to be performed every 6 weeks (+/- 3 working days) from randomisation (regardless of the timing of treatment cycles) until disease progression is documented. Patients who discontinue protocol treatment for reasons other than disease progression will have tumour assessments every 6 weeks until documented disease progression. Patients may continue to receive additional cycles of therapy until progressive disease or intolerable toxicity.
Quality of Life assessment, will be measured by EORTC QLQ-C30 and QLQ-BR23 questionnaires, which will be completed by patients.
The primary endpoint for the trial is progression free survival calculated from the date of randomization until the date of progression or the date of death whatever the reason of death. The analysis of Progression-Free Survival is planned to take place when 615 progressions or deaths have been observed. One interim safety analysis is planned and will take place when 50 patients of each arm have completed at least one cycle of study treatment. It is anticipated that up to 170 active study centres will participate, and that accrual will be completed in approximately 30 months.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
-
Quilmes, Argentina
-
Rosario, Argentina
-
San Martin, Argentina
-
Tucuman, Argentina
-
-
-
-
-
Gomel, Belarus
-
Grodno, Belarus
-
Minsk, Belarus
-
Vitebsk, Belarus
-
-
-
-
-
Bruxelles, Belgium
-
Liège, Belgium
-
-
-
-
-
Curitiba, Brazil
-
Porto Alegre, Brazil
-
Santo Andre, Brazil
-
Sao Paulo, Brazil
-
-
-
-
-
Plovdiv, Bulgaria
-
Sofia, Bulgaria
-
Stara Zagora, Bulgaria
-
-
-
-
-
Brno, Czechia
-
Jihlava, Czechia
-
-
-
-
-
Tallinn, Estonia
-
-
-
-
-
Angers, France
-
Caen, France
-
Dijon, France
-
Le Mans, France
-
Lorient, France
-
Lyon, France
-
Montpellier, France
-
Nantes, France
-
Saint-Brieuc, France
-
Saint-Cloud, France
-
Saint-Herblain, France
-
Tours, France
-
Villejuif, France
-
-
-
-
-
Budapest, Hungary
-
Szekesfehervar, Hungary
-
Szolnok, Hungary
-
-
-
-
-
Aurangabad, India
-
Bangalore, India
-
Bhopal, India
-
Calcutta, India
-
Calicut, India
-
Jaipur, India
-
Mumbai, India
-
Patna, India
-
Pune, India
-
Trivandrum, India
-
-
-
-
-
Avellino, Italy
-
Cagliari, Italy
-
Cremona, Italy
-
Fabriano, Italy
-
Milano, Italy
-
Monza, Italy
-
Padova, Italy
-
Pisa, Italy
-
Rozzano, Italy
-
Verona, Italy
-
-
-
-
-
Chihuahua, Mexico
-
Leon, Mexico
-
Mexico City, Mexico
-
Saltillo, Mexico
-
-
-
-
-
Bialystok, Poland
-
Gdansk, Poland
-
Krakow, Poland
-
Lodz, Poland
-
Lubin, Poland
-
Warsawa, Poland
-
-
-
-
-
Arkhangelsk, Russian Federation
-
Chelyabinsk, Russian Federation
-
Moscow, Russian Federation
-
Ryazan, Russian Federation
-
Saratov, Russian Federation
-
St-Petersburg, Russian Federation
-
Stavropol, Russian Federation
-
Tambov, Russian Federation
-
Ufa, Russian Federation
-
Vladimir, Russian Federation
-
Volgograd, Russian Federation
-
-
-
-
-
Nis, Serbia
-
Sremska Kamenica, Serbia
-
-
-
-
-
Durban, South Africa
-
Kimberley, South Africa
-
Pretoria, South Africa
-
Sandton, South Africa
-
-
-
-
-
Barcelona, Spain
-
Lleida, Spain
-
Madrid, Spain
-
Oviedo, Spain
-
Valencia, Spain
-
-
-
-
-
Genolier, Switzerland
-
Lausanne, Switzerland
-
Winterthur, Switzerland
-
-
-
-
-
Taipei, Taiwan
-
Taoyuan, Taiwan
-
-
-
-
-
Cherkasy, Ukraine
-
Dnipropetrovsk, Ukraine
-
Donetsk, Ukraine
-
Khmelnytskyï, Ukraine
-
Kyiv, Ukraine
-
Simferopol, Ukraine
-
-
-
-
-
Belfast, United Kingdom
-
Chelmsford, United Kingdom
-
Keighley, United Kingdom
-
London, United Kingdom
-
Nottingham, United Kingdom
-
Peterborough, United Kingdom
-
Portsmouth, United Kingdom
-
Sheffield, United Kingdom
-
Southend-on-Sea, United Kingdom
-
Sutton, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- female patients
- 21 years of age or older
- histologically/cytologically confirmed carcinoma of the breast
- documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy
- either one, two or three prior chemotherapy regimens
- prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs
- measurable or non-measurable disease according to RECIST 1.1
- Karnofsky performance score of at least 70 %
- adequate haematological, hepatic and renal functions
- ECG without clinically relevant abnormality
Exclusion Criteria:
- known or clinical evidence of brain metastasis or leptomeningeal involvement
- pulmonary lymphangitis or symptomatic pleural effusion
- any serious, concurrent uncontrolled medical disorder
- history of second primary malignancy
- preexisting motor/sensory peripheral neuropathy
- known history of HIV infection
- prior therapy with capecitabine and/or vinca-alkaloids
- history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs
- known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
- pregnancy or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vinflunine plus Capecitabine
Patients received (in combination with capecitabine) • Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks. |
Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Other Names:
|
Active Comparator: Capecitabine single-agent
Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
|
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: Baseline up to 2 years 7 months
|
PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause. The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last. |
Baseline up to 2 years 7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Baseline upto 3 years 10 months
|
The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause.
The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.
|
Baseline upto 3 years 10 months
|
Overall Response Rate (ORR)
Time Frame: Baseline upto 2 years 7 months
|
ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.
|
Baseline upto 2 years 7 months
|
Disease Control Rate
Time Frame: Baseline up to 2 years 7 months
|
Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.
|
Baseline up to 2 years 7 months
|
Duration of Response
Time Frame: Baseline up to 2 years 7 months
|
Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.
|
Baseline up to 2 years 7 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jean-Claude VEDOVATO, Pierre Fabre Medicament
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L00070 IN 305 B0
- 2008-004171-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Vinflunine plus Capecitabine
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Withdrawn
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Veeda OncologyBristol-Myers SquibbCompletedNon-Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompletedLung Cancer | Carcinoma, Small CellUnited States
-
Institute of Cancer Research, United KingdomSt George's Healthcare NHS TrustCompletedLocally-advanced or Metastatic Penile NeoplasmsUnited Kingdom
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingCancer | Metastatic | Breast | Triple Negative | Disseminated Tumor CellUnited States
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHER2 Positive Metastatic Breast CancerChina
-
Pierre Fabre MedicamentCompletedMalignant Neoplasm of BreastChina, Taiwan, Singapore
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompleted